Skip to main content
. 2021 Mar 2;9(3):209. doi: 10.3390/vaccines9030209

Figure 3.

Figure 3

Multivalent protein formulations. (A) The PcpA, PhtD, PlyD1 multivalent vaccine consisting of recombinant PcpA and PhtD along with the PlyD1 pneumolysin toxoid. (B) YLN hybrid construct consisting of the YPT and NEEK conserved domains of CbpA fused with the N- and C-teriminus, respectively, of the inactive L460D pneumolysin toxoid. 6.1. PcpA/PhtD/pneumolysin toxoid multivalent vaccine.